Reata Pharmaceuticals, Inc. (RETA) is a Biotechnology company in the Healthcare sector, currently trading at $172.36. It has a SharesGrow Score of 23/100, indicating a weak investment profile with 0 out of 7 criteria passed.
Analyst consensus target is RETA = $63 (-63.6% upside).
Financials: revenue is $2M, -39.8%/yr average growth. Net income is $312M (loss), growing at -3.4%/yr. Net profit margin is -14075% (negative). Gross margin is 100% (+469.1 pp trend).
Balance sheet: total debt is $119M with negative equity of -$66M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 6.75 (strong liquidity). Debt-to-assets is 23.2%. Total assets: $514M.
Analyst outlook: 4 / 10 analysts rate RETA as buy (40%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 62/100 (Partial), Future 16/100 (Fail), Income 10/100 (Fail).
